Halozyme Therapeutics, Inc. (HALO)

Price$68.14

Value ScoreC

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-19.45%

Price vs S&P 500 (4W)-0.94%

VGM Score55.00

Market Capitalization$7.89B

P/E Ratio (Annual)24.91x

All Metrics

P/CF (Annual)12.11x

Book Value / Share (Quarterly)$1.85

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)28.38%

Cash Flow / Share (Quarterly)$3.21

Price vs S&P 500 (YTD)-12.06%

Gross Margin (TTM)82.79%

Net Profit Margin (TTM)23.13%

EPS (TTM)$2.78

10-Day Avg Trading Volume1.75M

EPS Excl Extra (TTM)$2.78

Revenue Growth (5Y)39.16%

EPS (Annual)$2.56

ROI (Annual)14.46%

Gross Margin (Annual)83.62%

Net Profit Margin (5Y Avg)44.37%

Cash / Share (Quarterly)$2.69

P/E Basic Excl Extra (TTM)22.62x

Revenue Growth QoQ (YoY)42.23%

EPS Growth (5Y)22.89%

P/E Normalized (Annual)24.91x

ROA (Last FY)12.55%

Revenue Growth TTM (YoY)39.12%

EBITD / Share (TTM)$4.89

ROE (5Y Avg)286.14%

Operating Margin (TTM)33.58%

Cash Flow / Share (Annual)$3.03

P/B Ratio35.93x

P/B Ratio (Quarterly)34.86x

Net Income / Employee (Annual)$749,100

EV / Revenue (TTM)6.45x

Net Interest Coverage (TTM)143.47x

ROA (TTM)14.73%

EPS Growth QoQ (YoY)30.96%

EV / EBITDA (TTM)16.35x

EPS Incl Extra (Annual)$2.56

Current Ratio (Annual)4.66x

Quick Ratio (Quarterly)2.14x

3-Month Avg Trading Volume1.74M

52-Week Price Return21.58%

EV / Free Cash Flow (Annual)27.26x

P/E Incl Extra (TTM)22.62x

Revenue / Employee (TTM)$3,566,100

Tangible BV / Share (Quarterly)$1.32

P/S Ratio (Annual)5.65x

Asset Turnover (Annual)0.55x

52-Week High$82.22

Operating Margin (5Y Avg)45.17%

EPS Excl Extra (Annual)$2.56

CapEx CAGR (5Y)159.60%

26-Week Price Return-3.52%

Quick Ratio (Annual)3.30x

13-Week Price Return-3.87%

Total Debt / Equity (Annual)43.89x

Current Ratio (Quarterly)2.76x

Enterprise Value$9.73B

Revenue / Share Growth (5Y)42.91%

Asset Turnover (TTM)0.64x

Book Value / Share Growth (5Y)-18.01%

Revenue / Employee (Annual)$3,301,700

Inventory Turnover (Annual)1.44x

Pretax Margin (Annual)33.43%

Cash / Share (Annual)$1.21

3-Month Return Std Dev30.83%

Gross Margin (5Y Avg)81.05%

Net Income / Employee (TTM)$824,700

EBITDA CAGR (5Y)29.63%

EBITDA Interim CAGR (5Y)47.65%

ROE (Last FY)649.18%

Net Interest Coverage (Annual)12.91x

EPS Basic Excl Extra (Annual)$2.56

P/FCF (TTM)17.54x

Receivables Turnover (TTM)3.96x

EV / Free Cash Flow (TTM)25.61x

Total Debt / Equity (Quarterly)9.76x

EPS Incl Extra (TTM)$2.78

Receivables Turnover (Annual)3.73x

ROI (TTM)16.59%

P/S Ratio (TTM)5.23x

Pretax Margin (5Y Avg)44.82%

Revenue / Share (Annual)$11.27

Tangible BV / Share (Annual)$-5.81

Forward P/E7.55x

Free OCF CAGR (5Y)46.43%

Price vs S&P 500 (52W)-6.63%

P/E Ratio (TTM)22.62x

EPS Growth TTM (YoY)-26.21%

Year-to-Date Return-1.13%

5-Day Price Return-2.61%

EPS Normalized (Annual)$2.56

ROA (5Y Avg)19.55%

Net Profit Margin (Annual)22.69%

Month-to-Date Return4.52%

Cash Flow / Share (TTM)$2.37

EBITD / Share (Annual)$4.36

EPS Growth (3Y)21.17%

Operating Margin (Annual)33.19%

LT Debt / Equity (Annual)43.89x

P/CF (TTM)11.65x

ROI (5Y Avg)21.11%

P/E Excl Extra (TTM)22.62x

LT Debt / Equity (Quarterly)8.81x

EPS Basic Excl Extra (TTM)$2.78

P/TBV (Quarterly)55.21x

P/B Ratio (Annual)162.13x

Inventory Turnover (TTM)1.62x

Pretax Margin (TTM)33.37%

Book Value / Share (Annual)$0.41

Price vs S&P 500 (13W)-13.62%

Net Margin Growth (5Y)-14.00%

Beta0.88x

P/FCF (Annual)22.12x

Revenue / Share (TTM)$12.28

ROE (TTM)126.27%

52-Week Low$51.06

vGradeC

gGradeB

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 261.60est. 1.56

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

3.80

Industry Peers — Biological Products(178)

Symbol	Value Score	Growth Score	Momentum Score	Price
HALOHalozyme Therapeutics, Inc.	C	B	C	$68.14
AMGNAmgen Inc	C	C	C	$329.13
GILDGilead Sciences Inc	C	B	C	$131.10
ARGXargenx SE American Depositary Shares	D	A	C	$836.09
RVMDRevolution Medicines, Inc. Common Stock	F	—	A	$163.68
BIIBBiogen Inc. Common Stock	B	D	B	$192.23
BNTXBioNTech SE American Depositary Share	C	C	C	$91.70
MRNAModerna, Inc. Common Stock	C	B	B	$46.06
NBIXNeurocrine Biosciences Inc	C	B	B	$161.00
EXELExelixis Inc	C	B	B	$50.28
KRYSKrystal Biotech, Inc. Common Stock	D	B	B	$298.10

About

Halozyme Therapeutics develops oncology therapies that target human enzymes to alter tumor progression. The company advances its pipeline through both internal development and partnerships with biopharmaceutical companies to commercialize its proprietary technology. Operations are primarily US-based with minimal international assets.